Viral Inactivation Kits

Viral Inactivation Kits Market Outlook

The global Viral Inactivation Kits market is projected to reach USD 1.5 billion by 2035, growing at a robust CAGR of 10.5% during the forecast period from 2025 to 2035. The increasing prevalence of viral infections and the growing demand for safety in blood products and vaccines are significantly driving this market. The rising awareness regarding the importance of viral safety in biological products and advancements in technology for effective viral inactivation are also contributing to market growth. Moreover, the surge in research and development activities in the pharmaceutical and biotechnology sectors is expected to further bolster the adoption of viral inactivation kits. The heightened regulatory scrutiny on the safety of biological products and the need for effective inactivation methods are paramount factors fostering the growth of this industry.

Growth Factor of the Market

The growth of the Viral Inactivation Kits market can be attributed to several factors. Firstly, the global rise in viral outbreaks and infectious diseases has heightened the focus on ensuring the safety of blood products, vaccines, and cells used in therapies. This has led to increased investments from pharmaceutical companies in research and development to enhance safety protocols. Furthermore, the rapid advancements in technology, such as the development of more effective viral inactivation methods like nanofiltration and chemical inactivation, are also playing a significant role in the market's expansion. The demand for viral inactivation techniques for emerging therapies, including gene and cell therapies, is on the rise, pushing companies to innovate and expand their product offerings. Lastly, stringent regulations imposed by health authorities around the world regarding the safety of blood and biologics significantly boosts the demand for viral inactivation kits, as companies are mandated to comply with these rigorous standards.

Key Highlights of the Market

• The market is expected to grow significantly due to rising concerns about viral contamination in biological products.
• Technological advancements in viral inactivation methods are contributing to increased adoption.
• North America is projected to hold the largest market share due to advanced healthcare infrastructure.
• Pharmaceutical and biotechnology companies are the primary end-users driving market demand.
• Emerging economies in Asia Pacific are expected to witness substantial growth opportunities in the coming years.

By Product Type

Kits with Filtration Systems:

Kits with filtration systems represent a prominent segment in the viral inactivation kits market, primarily due to their efficiency in physically removing viruses from biological fluids. These kits typically employ membrane filtration techniques that can effectively separate viral particles from valuable therapeutic products, such as blood plasma and vaccines. As the demand for high-purity biological materials increases, the adoption of filtration systems is expected to grow significantly. Moreover, advancements in membrane technology have led to the development of more selective filters that can target specific virus sizes, enhancing their effectiveness. The ability of filtration systems to work in conjunction with other inactivation methods further bolsters their utility in diverse applications, making them a preferred choice among end-users.

Kits with UV Irradiation Systems:

Kits equipped with UV irradiation systems are gaining traction in the market due to their proven ability to inactivate a broad spectrum of viruses effectively. Ultraviolet light has been recognized as a powerful method for disrupting viral DNA or RNA, rendering viruses incapable of replication. This method is particularly appealing as it does not require the addition of chemical agents, thus maintaining the integrity of the biological product. The increasing awareness of the need for non-chemical inactivation methods in sensitive applications, such as cell and gene therapies, is expected to drive the growth of this segment. Furthermore, advancements in UV technology, including the development of more efficient and compact UV systems, are likely to enhance the appeal of these kits in various healthcare settings.

Kits with Low pH Solutions:

Kits utilizing low pH solutions for viral inactivation leverage the concept of acidic environments to denature and inactivate viral proteins effectively. This method is particularly advantageous for certain virus types that are susceptible to pH changes, and it is widely employed in the processing of blood products and vaccines. The growing emphasis on the use of biocompatible and environmentally friendly inactivation methods is boosting the adoption of low pH solution kits. Additionally, researchers are continually looking for ways to optimize the concentrations and exposure times to maximize efficiency while minimizing potential damage to the therapeutic components. The versatility of this method across multiple applications makes it a valuable option in the viral inactivation kits market.

Kits with Heat Treatment:

Kits that incorporate heat treatment as a viral inactivation method have long been recognized for their effectiveness in ensuring the safety of biological products. Heat treatment works by denaturing viral proteins, thereby inactivating the virus. This method is especially beneficial for heat-stable products and has been widely utilized in the inactivation of viruses in blood plasma and vaccines. With the continuous development of heat treatment protocols, such as pasteurization techniques, the efficiency and safety of these kits are expected to improve further. The increasing regulatory requirements surrounding viral safety also drive the demand for heat treatment kits, as they are viewed as a reliable and effective method for viral inactivation.

Kits with Pasteurization:

Kits featuring pasteurization processes are essential in the viral inactivation landscape, particularly for blood products and certain vaccines. Pasteurization involves heating biological materials to a specific temperature for a defined period, effectively inactivating a wide range of viruses while preserving the integrity of the product. This method is recognized for its simplicity and effectiveness, driving its adoption in various applications. As the focus on product safety increases, pasteurization kits are likely to become more prevalent, especially in regions with stringent regulatory requirements. Additionally, ongoing research is aimed at optimizing pasteurization parameters to enhance the efficacy of the process, ensuring broader acceptance and utilization within the healthcare industry.

By Application

Blood Products:

Blood products represent a significant application area for viral inactivation kits, primarily due to the critical need for safety in transfusion medicine. The risk of viral transmission through blood products necessitates rigorous safety measures, including effective viral inactivation. The growing awareness of viral safety in blood banks has led to increased adoption of viral inactivation kits designed specifically for blood products. Moreover, the rising incidence of transfusion-transmitted infections has escalated the demand for these kits, as healthcare providers strive to adhere to regulatory standards and ensure patient safety. The continuous innovation in viral inactivation technologies tailored for blood products is expected to further fuel market growth in this segment.

Vaccines:

In the vaccine sector, the need for viral inactivation is paramount to ensure the safety and efficacy of vaccines administered to populations. As vaccine development accelerates, especially in response to global health crises, the demand for reliable viral inactivation methods is on the rise. Viral inactivation kits are employed in various vaccine production processes to eliminate potential viral contaminants, thus safeguarding public health. The increasing number of vaccine candidates, particularly in the context of emerging infectious diseases, is likely to propel the growth of this market segment. Additionally, advancements in vaccine technology are driving the need for more sophisticated viral inactivation methods, further enhancing the market for these kits.

Cell Therapy Products:

With the rapid advancements in cell therapy, the need for effective viral inactivation methods within this application is increasingly critical. Cell therapies, which often involve manipulating human cells, necessitate stringent safety measures to prevent viral contamination that may compromise patient safety. Viral inactivation kits designed for cell therapy products are tailored to meet these stringent safety standards and ensure that the final product is free from viral contaminants. The steady growth in the cell therapy market, coupled with rising investments in research and development, is expected to significantly boost the demand for viral inactivation kits in this application area.

Tissue Products:

Tissue products, including grafts and transplants, are also vulnerable to viral contamination, making the role of viral inactivation kits in this area critical. The need for rigorous safety measures has led to the implementation of viral inactivation processes in tissue banks to mitigate the risk of viral transmission. The increasing number of tissue transplant procedures globally is driving the demand for viral inactivation kits tailored for this application. As regulatory authorities continue to emphasize the importance of viral safety in tissue products, the market for these kits is expected to see substantial growth. The ongoing research aimed at developing more effective and efficient viral inactivation methods for tissue products will further enhance this segment’s growth potential.

Stem Cell Products:

Stem cell products are at the forefront of regenerative medicine, and ensuring their safety through effective viral inactivation is of utmost importance. The use of stem cells in therapeutic applications necessitates meticulous processing to eliminate viral risks. Viral inactivation kits designed specifically for stem cell products play a critical role in mitigating these risks and ensuring patient safety. The rising interest in stem cell therapy and the expanding clinical applications of these products are contributing to the growth of this market segment. Furthermore, as more stem cell therapies move towards commercialization, the demand for reliable viral inactivation solutions is expected to increase significantly.

By End User

Pharmaceutical and Biotechnology Companies:

Pharmaceutical and biotechnology companies are the primary end-users of viral inactivation kits, given their extensive involvement in the development and manufacturing of biological products. These companies face stringent regulatory requirements regarding the safety of their products, driving the adoption of viral inactivation solutions. The increasing investment in research and development within these sectors further contributes to the demand for effective viral inactivation methods. As companies strive to innovate and enhance the safety profiles of their products, the reliance on viral inactivation kits is expected to grow. Moreover, the competitive landscape in these industries necessitates adherence to safety standards, positioning viral inactivation kits as essential components in the production processes.

Contract Research Organizations:

Contract Research Organizations (CROs) are also significant end-users of viral inactivation kits, as they provide essential services in research, trials, and product development for pharmaceutical and biotechnology companies. The growing reliance on CROs for specialized research services necessitates the inclusion of viral inactivation techniques in their protocols to ensure compliance with regulatory standards. As the demand for outsourced research services increases, particularly in the context of vaccine development and other biological products, the adoption of viral inactivation kits is likely to grow. The dynamic nature of the CRO sector, coupled with advancements in viral inactivation technologies, will enhance the role of these kits in supporting the research and development processes.

Academic and Research Institutes:

Academic and research institutes play a crucial role in advancing knowledge and technology, and the need for viral inactivation kits in these settings is growing. These institutes are often involved in cutting-edge research that includes the development of therapeutic products, which necessitates the implementation of robust viral inactivation protocols. The increasing focus on studying infectious diseases and the safety of biological materials in academic research is expected to drive the demand for viral inactivation kits. Moreover, as collaborations between academic institutions and industry partners continue to expand, the need for effective viral safety measures will further reinforce the importance of these kits in research settings.

Hospitals and Diagnostic Laboratories:

Hospitals and diagnostic laboratories function as critical components of the healthcare system, and the requirement for viral inactivation kits in these environments is essential for patient safety. These facilities are involved in processing blood products and conducting diagnostic tests, necessitating stringent safety measures to prevent viral transmission. The increasing volume of diagnostic testing and blood transfusions is driving the demand for effective viral inactivation solutions. Additionally, as the focus on patient safety intensifies, hospitals and diagnostic laboratories are likely to invest in advanced viral inactivation kits to comply with regulatory standards and ensure the safety of their procedures. The ongoing evolution of healthcare practices will continue to shape the demand for viral inactivation kits in these settings.

By Virus Type

Enveloped Viruses:

Enveloped viruses are among the most common viral contaminants in biological products, making their inactivation a critical priority. Kits designed to inactivate enveloped viruses employ a range of methods, including chemical agents, heat treatment, and UV irradiation, tailored to effectively target these pathogens. The rising incidence of enveloped viral infections, such as HIV and Hepatitis B, has heightened the demand for reliable viral inactivation solutions. As healthcare providers and manufacturers strive to meet stringent regulatory requirements, the adoption of kits specifically targeting enveloped viruses is expected to grow significantly. Continuous advancements in technology aimed at enhancing the efficacy of these kits will further bolster their utilization in various applications.

Non-Enveloped Viruses:

Non-enveloped viruses, while often more resilient to standard inactivation methods, also pose a serious risk in biological products. Kits designed to inactivate non-enveloped viruses must employ rigorous methods to ensure complete elimination of these pathogens. With the increasing focus on safety in blood transfusion and vaccine production, the demand for viral inactivation kits targeting non-enveloped viruses is on the rise. The growing awareness of the risks associated with non-enveloped viruses, such as Hepatitis A and Poliovirus, is driving the market for specialized kits. Innovations in viral inactivation technologies tailored to effectively combat non-enveloped viruses will likely enhance the market's growth potential in this segment.

By Region

The Viral Inactivation Kits market is witnessing significant regional variations, with North America leading the charge, anticipated to hold the largest market share throughout the forecast period. The region's advanced healthcare infrastructure, substantial investments in research and development, and stringent regulatory requirements contribute to the dominance of this market. Furthermore, the increasing prevalence of infectious diseases and the growing focus on safety in biological products are accelerating the adoption of viral inactivation kits in North America. Moreover, the region is expected to experience a CAGR of 11.2% as pharmaceutical and biotechnology companies continue to prioritize viral safety in their operations.

Europe follows closely as a key player in the viral inactivation kits market, driven by similar factors as those in North America. The European market is projected to reach USD 500 million by 2035 due to the rising number of research initiatives, stringent regulatory frameworks, and an increasing focus on viral safety in healthcare. The Asia Pacific region, although currently smaller in comparison, is expected to witness rapid growth fueled by the rising adoption of advanced healthcare technologies, increased investments in the pharmaceutical sector, and growing awareness about the importance of viral inactivation. The market in Asia Pacific is anticipated to grow at a remarkable CAGR of 12.0%, showcasing substantial opportunities for industry players looking to penetrate emerging markets.

Opportunities

The Viral Inactivation Kits market is poised for substantial growth due to various opportunities on the horizon. The increasing incidence of viral outbreaks and the subsequent urgency to ensure safety standards in blood products and vaccines create a pressing need for advanced viral inactivation solutions. Companies that can innovate and provide cost-effective, efficient products tailored to specific applications will likely capture significant market share. Furthermore, the expansion of biopharmaceutical and biotechnology sectors, particularly in emerging markets, presents an untapped opportunity for viral inactivation kit manufacturers. As these regions increasingly focus on improving healthcare infrastructure and regulatory compliance, the demand for viral inactivation kits is expected to rise sharply, underscoring the potential for industry growth. Collaborations and partnerships with research institutions and healthcare providers can also lead to the development of tailored solutions that cater to specific viral inactivation needs, further enhancing market opportunities.

Another substantial opportunity lies in the continuous technological advancements in viral inactivation methods. Innovations, such as nanofiltration and improved UV technologies, are opening new avenues for effective kit development, targeting previously hard-to-inactivate viruses. The rising focus on personalized medicine and novel therapeutic approaches, such as gene and cell therapies, necessitates stringent safety measures, providing further impetus for the growth of viral inactivation kits. Manufacturers that invest in research and development to create cutting-edge, versatile kits that can cater to a variety of applications will be well-positioned to capitalize on emerging trends in the industry. Overall, the interplay of rising demand, technological advancements, and an evolving regulatory landscape offers a multitude of opportunities for businesses in the viral inactivation kits market.

Threats

While the Viral Inactivation Kits market appears promising, several threats could hinder its growth. One of the most pressing challenges is the rapid pace of technological advancements that could render existing inactivation methods obsolete. Continuous innovation in the field necessitates that companies remain agile and adaptable to new technologies and methodologies; failure to do so may result in lost market share to more forward-thinking competitors. Additionally, the evolving regulatory landscape poses a potential threat, as stringent compliance requirements may increase operational costs and complexity for manufacturers. The need for ongoing investment in research, quality assurance, and regulatory compliance can strain resources, particularly for smaller companies that may lack the necessary infrastructure to meet these challenges.

Moreover, the increasing competition in the viral inactivation kits market presents another threat. With numerous players entering the market, price wars and the pressure to reduce costs may impact profit margins significantly. Companies may be compelled to compromise on quality to remain competitive, potentially affecting the efficacy and reliability of their products. Furthermore, supply chain disruptions due to global events or geopolitical tensions can lead to delays in manufacturing and distribution, adversely affecting market dynamics. As the industry evolves, it is crucial for companies to navigate these threats while continuing to innovate and prioritize quality to maintain their competitive edge in the viral inactivation kits market.

Competitor Outlook

• Thermo Fisher Scientific
• Sartorius AG
• Merck KGaA
• GE Healthcare
• Pall Corporation
• Bio-Rad Laboratories, Inc.
• Octapharma AG
• Fresenius Kabi AG
• Lonza Group AG
• Takara Bio Inc.
• Viropro Inc.
• Shenzhen Genyx Biotech Co., Ltd.
• Asahi Kasei Corporation
• GSK Biologicals
• Clean Biologics

The competitive landscape of the Viral Inactivation Kits market is marked by the presence of numerous players, each vying for market share through innovative product offerings and strategic partnerships. Major companies like Thermo Fisher Scientific and Sartorius AG are at the forefront, leveraging their extensive research and development capabilities to deliver cutting-edge solutions. These companies often focus on expanding their product lines to meet the diverse needs of end-users across various applications. The competitive dynamics in the market are further intensified by mergers and acquisitions, as companies look to enhance their technological capabilities and broaden their market reach. This trend is indicative of a rapidly evolving industry where innovation and collaboration are key drivers of growth.

Moreover, companies such as Merck KGaA and GE Healthcare are renowned for their commitment to quality and compliance, which resonates with customers seeking reliable viral inactivation solutions. These companies prioritize rigorous testing and regulatory adherence, which can significantly bolster their market position. Furthermore, as the demand for viral inactivation kits grows, emerging players like Shenzhen Genyx Biotech Co., Ltd. and Clean Biologics are also gaining traction through niche offerings that cater to specific market segments. The continuous evolution of the market landscape underscores the importance of agility and responsiveness among competitors, positioning those who can adapt quickly as leaders in the viral inactivation kits market.

In summary, the competitive landscape of the Viral Inactivation Kits market is characterized by a blend of established players and emerging firms, each contributing to the innovation and advancement of viral safety measures in the healthcare sector. The ongoing focus on enhancing product efficacy, meeting stringent regulatory requirements, and addressing the evolving needs of end-users will shape the future of this market. As the industry progresses, collaboration between academia, research institutes, and industry players will become increasingly vital in driving the development of novel viral inactivation technologies and solutions, ultimately benefiting public health and safety.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Merck KGaA
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Sartorius AG
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Viropro Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 GE Healthcare
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Octapharma AG
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Lonza Group AG
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Clean Biologics
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 GSK Biologicals
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Takara Bio Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Pall Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Fresenius Kabi AG
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Asahi Kasei Corporation
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Thermo Fisher Scientific
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Bio-Rad Laboratories, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Shenzhen Genyx Biotech Co., Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Viral Inactivation Kits Market, By End User
    • 6.1.1 Pharmaceutical and Biotechnology Companies
    • 6.1.2 Contract Research Organizations
    • 6.1.3 Academic and Research Institutes
    • 6.1.4 Hospitals and Diagnostic Laboratories
  • 6.2 Viral Inactivation Kits Market, By Virus Type
    • 6.2.1 Enveloped Viruses
    • 6.2.2 Non-Enveloped Viruses
  • 6.3 Viral Inactivation Kits Market, By Application
    • 6.3.1 Blood Products
    • 6.3.2 Vaccines
    • 6.3.3 Cell Therapy Products
    • 6.3.4 Tissue Products
    • 6.3.5 Stem Cell Products
  • 6.4 Viral Inactivation Kits Market, By Product Type
    • 6.4.1 Kits with Filtration Systems
    • 6.4.2 Kits with UV Irradiation Systems
    • 6.4.3 Kits with Low pH Solutions
    • 6.4.4 Kits with Heat Treatment
    • 6.4.5 Kits with Pasteurization

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Viral Inactivation Kits Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Viral Inactivation Kits market is categorized based on

By Product Type

• Kits with Filtration Systems
• Kits with UV Irradiation Systems
• Kits with Low pH Solutions
• Kits with Heat Treatment
• Kits with Pasteurization

By Application

• Blood Products
• Vaccines
• Cell Therapy Products
• Tissue Products
• Stem Cell Products

By End User

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Academic and Research Institutes
• Hospitals and Diagnostic Laboratories

By Virus Type

• Enveloped Viruses
• Non-Enveloped Viruses

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Thermo Fisher Scientific
• Sartorius AG
• Merck KGaA
• GE Healthcare
• Pall Corporation
• Bio-Rad Laboratories, Inc.
• Octapharma AG
• Fresenius Kabi AG
• Lonza Group AG
• Takara Bio Inc.
• Viropro Inc.
• Shenzhen Genyx Biotech Co., Ltd.
• Asahi Kasei Corporation
• GSK Biologicals
• Clean Biologics